ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1133

Measured GFR Implemented in a US Clinical Practice: Accuracy of eGFR Cannot Be Assumed without Measured GFR

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Jameson, Robert L., Houston Methodist Hospital, Houston, Texas, United States
  • Nielsen, Jacob, Houston Methodist Hospital, Houston, Texas, United States
  • Yi, Xin, Houston Methodist Hospital, Houston, Texas, United States
  • Edwards, Angelina, Houston Methodist Hospital, Houston, Texas, United States
  • Bobart, Shane A., Houston Methodist Hospital, Houston, Texas, United States
  • Shafi, Tariq, Houston Methodist Hospital, Houston, Texas, United States
Background

In clinical practice, GFR estimated from serum creatinine (eGFR-CR) is often assumed to be accurate for individual patients and eGFR estimated from either serum cystatin C (eGFR-Cys) or both (eGFR-Cr-Cys) is considered the “confirmatory” test. However, without clinical availability of measured GFR (mGFR) these assumptions cannot be verified. We have implemented mGFR (4-hour plasma iohexol clearance; non-radiolabeled) as part of routine clinical care at a large urban academic medical center. The test is orderable in Epic and implemented in our outpatient infusion center. We present case studies to highlight that mGFR is essential for clinical practice and eGFR-Cys is not a universal confirmatory test for GFR.

Methods

We describe three patients that had simultaneous measurement of creatinine, cystatin C, and mGFR by 4-hour plasma iohexol clearance as part of routine clinical care. We defined eGFR to be accurate in assessing mGFR if it was within ± 5 mL/min/1.73m2 of the mGFR.

Results

See Table 1

Conclusion

Availability of mGFR in clinical practice is essential for interpretation of eGFR, when an accurate assessment is needed. Cystatin C eGFR’s should not automatically considered to be an mGFR replacement.